Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Telaprevir

FDA-approved product (tablet, oral), marketed as Incivek.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Telaprevir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Telaprevir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Telaprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

    NCT00528528 · start 2007-10

    Registered record
    Registry ID
    NCT00528528
    Conditions
    Chronic Hepatitis C
    Interventions
    Telaprevir; Peg-IFN-alfa-2a; Peg-IFN-alfa-2b; Ribavirin (RBV) tablet; Ribavirin (RBV) capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-10
    Completion
    2009-08
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionTelaprevir; Peg-IFN-alfa-2a; Peg-IFN-alfa-2b; Ribavirin (RBV) tablet +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

    NCT00535847 · start 2007-10

    Registered record
    Registry ID
    NCT00535847
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated interferon alfa 2a
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-10
    Completion
    2010-02
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated interferon alfa 2a
    PhasePhase 2
    Registry statusCompleted

  • A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

    NCT00420784 · start 2007-02

    Registered record
    Registry ID
    NCT00420784
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated Interferon Alfa 2a; Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-02
    Completion
    2009-04
    Enrolment
    465

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa 2a; Matching Placebo
    PhasePhase 2
    Registry statusCompleted

  • Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

    NCT00372385 · start 2006-08

    Registered record
    Registry ID
    NCT00372385
    Conditions
    Chronic Hepatitis C
    Interventions
    Ribavirin; Pegylated Interferon Alfa 2a; Placebo; Telaprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-08
    Completion
    2008-06
    Enrolment
    334

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionRibavirin; Pegylated Interferon Alfa 2a; Placebo; Telaprevir
    PhasePhase 2
    Registry statusCompleted

  • Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

    NCT00262483 · start 2005-12

    Registered record
    Registry ID
    NCT00262483
    Conditions
    Hepatitis C
    Interventions
    VX-950; ribavirin; peginterferon alfa-2a
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-12
    Completion
    2006-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionVX-950; ribavirin; peginterferon alfa-2a
    PhasePhase 2
    Registry statusCompleted